

*HART & HART, LLC*  
ATTORNEYS AT LAW  
1624 Washington Street  
Denver, CO 80203

William T. Hart, P.C.  
Will Hart

(303) 839-0061

harttrinen@aol.com  
Fax: (303) 839-5414

April 29, 2012

OTC Markets Group, Inc.  
304 Hudson Street, Second Floor  
New York, NY 10013

Re: Trulan Resources, Inc. f/k/a Hire International, Inc. (the "Issuer")

We have been asked to provide you an opinion with respect to the information publicly disclosed by the Issuer and published in the OTC Disclosure and News Service. This opinion is solely for the information of the addressee hereof, and OTC Markets Group is entitled to rely on such letter in determining whether the Issuer has made adequate current information publicly available within the meaning of Rule 144(c)(2) under the Securities Act of 1933. The undersigned grants OTC Markets Group, Inc. full and complete permission and rights to publish the letter in the OTC Disclosure and News Service for viewing by the public and regulators.

The undersigned is a U.S. resident and was retained by the Issuer for the purpose of rendering this opinion and related matters. This opinion is based on our knowledge of the law and facts as of the date hereof. The undersigned has examined such corporate records and other documents and such questions of law as we deemed appropriate for the purposes of rendering this opinion.

The undersigned was admitted to the Bar of the State of Colorado in 2009. The undersigned is permitted to practice before the Securities and Exchange Commission ("SEC") and has never been barred from practice in any of the foregoing jurisdictions.

In connection with the opinion set forth below, we have examined such corporate records and documents, including but not limited to, the Issuer's Certificate of Incorporation, By-Laws and minutes of meetings and actions of its Board of Directors and such other documents as we deemed relevant and necessary as a basis for the opinion hereafter set forth. In such examination, we have assumed the genuineness of all signatures set forth on each document, the authenticity of all original documents, and the conformity to original documents of all copies of such documents as may have been supplied to us during the course of our examination.

For the purposes of rendering this opinion, we have assumed that no person or entity has engaged in fraud or misrepresentation regarding the inducement relating to, or the execution or delivery of, the documents reviewed. Furthermore, we express no opinion as to the validity of any of the assumptions, form or content of any financial or statistical data contained therein. The

terms used in this opinion shall have the meaning ascribed to them in the documents relied upon in rendering our opinion.

Regarding the common stock of the Issuer, par value \$0.001, and preferred stock, par value \$0.001 (the "Securities"), in our opinion, the Annual Report for the year ended December 31, 2012 (filed on April 2, 2013) as published on the OTC Disclosure and News Service: (i) constitutes "adequate current public information" concerning the Securities of the Issuer and "is available" within the meaning of Rule 144(c)(2) under the Securities Act; (ii) includes all of the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the Securities under Rule 15c2-11 under the Securities Exchange Act of 1934 (the "Exchange Act"); (iii) complies as to form with the Pink OTC Markets' Guidelines for Providing Adequate Current Information, which are located on the Internet at [www.otcmarkets.com](http://www.otcmarkets.com); and (iv) has been posted through the OTC Disclosure and News Service. Furthermore, after reasonable investigation, we have no reason to believe that such information contains an untrue statement of a material fact, or omits to state a material fact, in order to make the statements made, in light of the circumstances under which they were made, not misleading.

Robert Rosner, Chief Executive Officer of the Issuer, was responsible for the preparation of the unaudited financial statements through December 31, 2012. The qualifications of Mr. Rosner are outlined in his biographical information set forth in the Information as published through the OTC Disclosure and News Service. Mr. Rosner has extensive experience in the requirements for proper financial reporting and disclosure for public companies. He is assisted in these matters by former Board of Director member Jeremy Stobie, who is a CPA with many years of experience in the reporting and disclosure requirements of public companies. Both have knowledge of the requirements of GAAP and the state and federal securities laws.

The Company's transfer agent is Pacific Stock Transfer Company and, to the best of our knowledge, is registered with the SEC. We have reviewed a copy of the shareholder list prepared by the transfer agent as of the current date to confirm that the number of outstanding shares set forth in the Information is correct. The undersigned has: (i) reviewed the Information published by the Issuer through the OTC Disclosure and News Service; and (ii) discussed the Information with management and a majority of the directors of the Issuer. To the best of our knowledge, and after reasonable inquiry of the Issuer's management and directors, there is no officer, director, 5% holder, or counsel currently under investigation by any federal or state regulatory authority for any violation of federal or state securities laws.


OTC Markets Group, Inc.  
April 29, 2013  
Page 3

This opinion is solely for the information of the addressee hereof and the other parties specifically identified in the first paragraph hereof, and is not to be quoted in whole or in part or otherwise referred to, nor is it to be filed with any governmental agency or other person without our prior written consent. Other than the addressee hereof and such other parties, no one is entitled to rely on this opinion. This opinion is based on our knowledge of the law and facts as of the date hereof. We assume no duty to communicate with you with respect to any matter which comes to our attention hereafter.

Thank you for your consideration and attention.

Very truly yours,

HART & HART, LLC



Will Hart

WH:tg

Trulan Letter OTC re Opinion 4-29-13